Cordis acquires two stent licences:
This article was originally published in Clinica
Cordis has extended its stent portfolio with the acquisition of the exclusive licences to two patents. These are for technologies providing flexible tubular sleeves. Cordis says it will initially focus the devices' commercialisation on vascular applications. The company's first coronary stent, unconnected with the licences mentioned, is being introduced in Europe with the international launch to follow later this year.